ECSP21013620A - Inhibición de la integrina alfa v beta 6 - Google Patents

Inhibición de la integrina alfa v beta 6

Info

Publication number
ECSP21013620A
ECSP21013620A ECSENADI202113620A ECDI202113620A ECSP21013620A EC SP21013620 A ECSP21013620 A EC SP21013620A EC SENADI202113620 A ECSENADI202113620 A EC SENADI202113620A EC DI202113620 A ECDI202113620 A EC DI202113620A EC SP21013620 A ECSP21013620 A EC SP21013620A
Authority
EC
Ecuador
Prior art keywords
beta
alpha
inhibition
assay
integrin
Prior art date
Application number
ECSENADI202113620A
Other languages
English (en)
Inventor
Bruce Rogers
Cheng Zhong
Kyle Konze
Blaise Lippa
Qi Qiao
Bryce A Harrison
Tyler Day
James Dowling
Aleksey I Gerasyuto;
Kristopher Hahn
Mats Svensson
Eugene Hickey
Byungchan Kim
fu-yang Lin
Dawn Troast
Matthew Bursavich
Brian Sosa
Andrea Bortolato
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of ECSP21013620A publication Critical patent/ECSP21013620A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen inhibidores de molécula pequeña de la integrina alfa V beta 6, y métodos para usarlos para tratar una serie de enfermedades y afecciones. Los solicitantes han descubierto nuevos compuestos inhibidores de la integrina alfa V beta 6 y han evaluado la posesión, el rendimiento y la utilidad de ejemplos representativos de tales compuestos, tanto para la potencia bioquímica (por ejemplo, mediante el uso del ensayo del Ejemplo 35 para evaluar los ensayos de polarización de fluorescencia de compuestos para la unión de alfa V beta 6) como las propiedades de permeabilidad in vitro (por ejemplo, mediante el uso del ensayo del Ejemplo 36 para evaluar la permeabilidad en MDCK).
ECSENADI202113620A 2018-08-29 2021-02-26 Inhibición de la integrina alfa v beta 6 ECSP21013620A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862724423P 2018-08-29 2018-08-29
US201962859457P 2019-06-10 2019-06-10

Publications (1)

Publication Number Publication Date
ECSP21013620A true ECSP21013620A (es) 2021-05-31

Family

ID=67809398

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202113620A ECSP21013620A (es) 2018-08-29 2021-02-26 Inhibición de la integrina alfa v beta 6

Country Status (23)

Country Link
US (5) US20200071322A1 (es)
EP (2) EP4086254B1 (es)
JP (2) JP7540998B2 (es)
KR (1) KR102852841B1 (es)
CN (2) CN118878533A (es)
AU (1) AU2019327475B2 (es)
BR (1) BR112021003859A2 (es)
CA (1) CA3109534A1 (es)
CL (1) CL2021000484A1 (es)
CO (1) CO2021002706A2 (es)
CR (1) CR20210109A (es)
DO (1) DOP2021000035A (es)
EC (1) ECSP21013620A (es)
ES (1) ES3019404T3 (es)
IL (1) IL280782A (es)
MA (1) MA51066A (es)
MX (1) MX2021002181A (es)
PE (1) PE20211640A1 (es)
PH (1) PH12021550404A1 (es)
SG (1) SG11202101913PA (es)
TW (1) TW202035400A (es)
UY (1) UY38353A (es)
WO (1) WO2020047239A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10604520B2 (en) 2016-09-07 2020-03-31 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
EP3558303A4 (en) 2016-12-23 2020-07-29 Pliant Therapeutics, Inc. AMINO ACID COMPOUNDS AND PROCESSES FOR USE
IL316954A (en) 2017-02-28 2025-01-01 Morphic Therapeutic Inc (Alpha-V)(beta-6)integrin inhibitors
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
DK3761980T3 (da) 2018-03-07 2024-01-29 Pliant Therapeutics Inc Aminosyreforbindelser og fremgangsmåder til anvendelse
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
UY38352A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
UY38353A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibición de integrina alfavbeta6
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
HUE070112T2 (hu) 2018-10-30 2025-05-28 Gilead Sciences Inc 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
WO2020210404A1 (en) 2019-04-08 2020-10-15 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物
CA3189071A1 (en) * 2020-09-11 2022-03-17 Xiaokai Li Skeletal muscle delivery platforms and methods of use
CU20230026A7 (es) 2020-11-19 2024-01-10 Pliant Therapeutics Inc Formas cristalinas de inhibidor de integrina y sales de estas
CN120957721A (zh) * 2023-02-14 2025-11-14 莫菲克医疗股份有限公司 抑制αvβ8整合素
EP4665458A1 (en) * 2023-02-14 2025-12-24 Morphic Therapeutic, Inc. Inhibiting alpha v beta8 integrin

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1993010091A2 (en) 1991-11-14 1993-05-27 Glaxo Group Limited Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
WO1993014077A1 (en) 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
ES2134870T3 (es) 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
KR19990076876A (ko) 1995-12-29 1999-10-25 스티븐 베네티아너 비트로넥틴 수용체 길항제
AU1295597A (en) 1995-12-29 1997-07-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
US20010034445A1 (en) 1995-12-29 2001-10-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997026250A1 (en) 1996-01-16 1997-07-24 Merck & Co., Inc. Integrin receptor antagonists
DE59706273D1 (de) 1996-03-20 2002-03-21 Hoechst Ag Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
PT891332E (pt) 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
JP2002511052A (ja) 1996-08-29 2002-04-09 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
WO1998018460A1 (en) 1996-10-30 1998-05-07 Merck & Co., Inc. Integrin antagonists
US5952341A (en) 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
CA2286239A1 (en) 1997-04-07 1998-10-15 Merck & Co., Inc. A method of treating cancer
AU7105498A (en) 1997-04-14 1998-11-11 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
AU1523199A (en) 1997-11-26 1999-06-15 Du Pont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as alphavbeta3 antagonists
EP1047425A4 (en) 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
HUP0100178A3 (en) 1997-12-17 2002-12-28 Merck & Co Inc Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
WO1999030713A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
BR9813769A (pt) 1997-12-17 2000-10-10 Merck & Co Inc Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste.
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO2000006169A1 (en) 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
CA2355874A1 (en) 1998-12-19 2000-06-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung .alpha.v.beta.6 integrin inhibitors
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
DZ3263A1 (fr) 1999-06-02 2000-12-07 Merck & Co Inc Antagonistes du recepteur de l'alpha v integrine
AU748949B2 (en) 1999-06-23 2002-06-13 Merck & Co., Inc. Integrin receptor antagonists
DE19933173A1 (de) 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
GB9929988D0 (en) 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
WO2001053297A1 (en) 2000-01-20 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
CA2397665A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US7119098B2 (en) 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
US20040254211A1 (en) 2000-09-14 2004-12-16 Arison Byron H Alpha v integrin receptor antagonists
WO2002022616A2 (en) 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
US20050004199A1 (en) 2000-09-18 2005-01-06 George Hartman Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
CA2436130A1 (en) 2001-01-29 2002-08-08 Ortho-Mcneil Pharmaceutical, Inc. Substituted indoles and their use as integrin antagonists
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
EP1387688A2 (en) 2001-05-03 2004-02-11 Merck & Co., Inc. Benzazepinone alpha v integrin receptor antagonists
US20040043988A1 (en) 2001-06-15 2004-03-04 Khanna Ish Kurmar Cycloalkyl alkanoic acids as intergrin receptor antagonists
DE10204789A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
JP4554364B2 (ja) 2002-08-16 2010-09-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インテグリンと選択的に結合するピペリジニル化合物
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
US20080045521A1 (en) 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
AU2008266228A1 (en) 2007-06-13 2008-12-24 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
CA2705916C (en) 2007-11-16 2016-01-05 Ube Industries, Ltd. Benzazepinone compound
US20120289481A1 (en) 2011-05-13 2012-11-15 O'neil Jennifer Compositions and methods for treating cancer
US9085606B2 (en) 2012-07-18 2015-07-21 Saint Louis University Beta amino acid derivatives as integrin antagonists
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015103643A2 (en) 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2015179823A2 (en) 2014-05-23 2015-11-26 The California Institute For Biomedical Research Lung localized inhibitors of alpha(v)beta 6
WO2016022851A1 (en) 2014-08-06 2016-02-11 Children's Medical Center Corporation Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
AU2016237099C1 (en) 2015-03-25 2023-01-19 Fujifilm Corporation Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
EP3288555A1 (en) 2015-04-30 2018-03-07 SciFluor Life Sciences, Inc. Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
KR20180107121A (ko) 2015-12-30 2018-10-01 세인트 루이스 유니버시티 팬 인테그린 길항제로서의 메타-아자사이클릭 아미노 벤조산 유도체
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
DE102016003731A1 (de) 2016-03-24 2017-09-28 Friedrich-Alexander-Universität Erlangen-Nürnberg Verfahren zum Erzeugen eines Kompositmaterials mit hierarchischer Porosität
US11192889B2 (en) 2016-07-05 2021-12-07 The Rockefeller University Tetrahydronaphthyridinepentanamide integrin antagonists
US10604520B2 (en) 2016-09-07 2020-03-31 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
JP7291624B2 (ja) 2016-11-01 2023-06-15 アローヘッド ファーマシューティカルズ インコーポレイテッド アルファ－ｖベータ－６インテグリンリガンド及びその使用
WO2018085552A1 (en) 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
WO2018085578A1 (en) 2016-11-02 2018-05-11 Saint Louis University Integrin inhibitors in combination with an agent which interacts with a chemokine receptor
EA201991123A1 (ru) 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
CA3042710A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
PL3538528T3 (pl) 2016-11-08 2021-05-31 Bristol-Myers Squibb Company Amidy pirolu jako inhibitory integryny alfa v
WO2018089353A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as alpha v integrin inhibitors
BR112019009245A2 (pt) 2016-11-08 2019-07-16 Bristol-Myers Squibb Company azol amidas e aminas como inibidores de alfav integrina
EP3558303A4 (en) 2016-12-23 2020-07-29 Pliant Therapeutics, Inc. AMINO ACID COMPOUNDS AND PROCESSES FOR USE
KR20190100232A (ko) 2016-12-29 2019-08-28 세인트 루이스 유니버시티 인테그린 길항제
IL316954A (en) 2017-02-28 2025-01-01 Morphic Therapeutic Inc (Alpha-V)(beta-6)integrin inhibitors
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
DK3761980T3 (da) 2018-03-07 2024-01-29 Pliant Therapeutics Inc Aminosyreforbindelser og fremgangsmåder til anvendelse
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
WO2020009889A1 (en) 2018-07-03 2020-01-09 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS
EP3843728B1 (en) 2018-08-29 2025-04-30 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
UY38353A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibición de integrina alfavbeta6
UY38352A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
WO2020210404A1 (en) 2019-04-08 2020-10-15 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds

Also Published As

Publication number Publication date
CA3109534A1 (en) 2020-03-05
US11739087B2 (en) 2023-08-29
CN118878533A (zh) 2024-11-01
EP4086254A1 (en) 2022-11-09
US12459942B2 (en) 2025-11-04
US20240376095A1 (en) 2024-11-14
EP4086254B1 (en) 2024-12-18
KR20210065935A (ko) 2021-06-04
AU2019327475B2 (en) 2025-06-05
US20200354359A1 (en) 2020-11-12
WO2020047239A1 (en) 2020-03-05
PE20211640A1 (es) 2021-08-24
IL280782A (en) 2021-04-29
BR112021003859A2 (pt) 2021-05-18
SG11202101913PA (en) 2021-03-30
US20220073511A1 (en) 2022-03-10
JP7540998B2 (ja) 2024-08-27
KR102852841B1 (ko) 2025-09-02
MX2021002181A (es) 2021-07-15
US20200071322A1 (en) 2020-03-05
AU2019327475A1 (en) 2021-03-11
CL2021000484A1 (es) 2021-09-03
US11021480B2 (en) 2021-06-01
JP2024161471A (ja) 2024-11-19
DOP2021000035A (es) 2021-06-30
JP2021535141A (ja) 2021-12-16
JP7829635B2 (ja) 2026-03-13
PH12021550404A1 (en) 2021-10-04
CR20210109A (es) 2021-06-24
US20200385384A1 (en) 2020-12-10
UY38353A (es) 2020-03-31
CN112805001B (zh) 2024-07-23
TW202035400A (zh) 2020-10-01
EP3617206A1 (en) 2020-03-04
CN112805001A (zh) 2021-05-14
CO2021002706A2 (es) 2021-05-20
MA51066A (fr) 2020-10-14
ES3019404T3 (en) 2025-05-20

Similar Documents

Publication Publication Date Title
ECSP21013620A (es) Inhibición de la integrina alfa v beta 6
WO2020047207A8 (en) Inhibitors of (alpha-v)(beta-6) integrin
CU24387B1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
BRPI0911105A2 (pt) compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seu uso
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
DOP2011000050A (es) Inhibidores de cmet
CL2011000242A1 (es) Uso de compuestos derivados de fenilaminopirimidina para tratar talasemia alfa, delta y anemia celular falciforme, talasemia mayor, talasemia menor, talasemia e-beta o talasemia beta falciforme, o para mejorar o retrasar los sintomas de las mismas y uso de un compuesto especifico para tratar la talasemia.
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
ECSP078055A (es) Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas
ECSP11011183A (es) Compuestos orgánicos
ECSP13012519A (es) Compuestos sustituidos de benzamida
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
PE20250667A1 (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2
CU23889B1 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antinflamatorios
PA8666701A1 (es) Nueva sal y polimorfos del inhibidor de la dpp-iv
CL2011002911A1 (es) Compuestos derivados de benzamidas, inhibidores de serina proteasa; composición farmacéutica; uso del compuesto para tratar cáncer.
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
MX2020009022A (es) Uso de alcoxipirazoles como inhibidores de la nitrificacion.
CL2019001804A1 (es) Activador de nrf2.
CL2023001673A1 (es) Nuevos compuestos como inhibidor dual del receptor de andrógenos y de la fosfodiesterasa
CL2019002661A1 (es) Compuestos antineoplásicos.
CL2022001393A1 (es) Composición para la preparación de alulosa y procedimiento para la preparación de alulosa mediante el
ECSP056205A (es) Nuevos bioisosteros de actinonina
GT200500382A (es) Sulfonamido-macrociclos y sus sales como inhibidores de tie2, composicion farmaceutica que comprende estos compuestos, metodo de prepararlos y su uso